After seeding gene therapy start-up Avrobio Inc. earlier this year, Atlas Venture stepped back up to the plate, joined by Clarus and SV Life Sciences, to fund the company’s $25 million series A. The round will accelerate development of Avrobio’s initial programs in Fabry disease and acute myeloid leukemia (AML), both expected to enter the clinic this year, and allow the company to expand its pipeline in rare diseases and solid and liquid cancers.